Ziphius Vaccines strengthens Leadership Team and provides Business Update

January 11, 2021 at 10:00 AM CET

  • Kristof Vercruysse appointed Chief Scientific Officer

  • Ziphius to attend 39th Annual J.P. Morgan Healthcare Conference

Ziphius Vaccines, a self-amplifying RNA company developing transformative infectious disease vaccines, today announced the appointment of Kristof Vercruysse as Chief Scientific Officer. Kristof will be responsible for the fast development progression of our lead compound ZIP-1642 and expanding our platform to multiple indications at Ziphius Vaccines.

 

Ziphius today also announced following Business Update:

  • Licensing agreement with UGhent

  • Expansion of Ziphius team in 2021 up to 46 members

  • Commercial manufacturing agreement with Univercells

  • Confirmation of our vaccine pipeline strategy

  • Compelling results of vaccine platform

“We are delighted that Kristof is joining our team as Chief Scientific Officer”, said Chris Cardon, Chief Executive Officer Ziphius Vaccines. “In Kristof, we found the ideal candidate to support the further development of our self-amplifying mRNA platform. Kristof’s experience and outstanding track record in the development of therapeutics and vaccines will be a critical asset for the fast development progression of our lead compound ZIP-1642 and expanding our platform to multiple indications at Ziphius Vaccines.”

Mr. Vercruysse, previous Ablynx, has been developing new chemical entities, peptides, antibodies and antibody-based drugs for almost 20 years and progressed multiple medicinal products from preclinical proof of concept to proof of concept in the clinic, three of which (Bridion, Angiox and Cablivi) have obtained marketing authorization. Kristof has a background in Biomedical Sciences from the Free University of Brussels, Belgium. Prior to joining Ziphius Vaccines, Kristof has been Director Early Development and Project Manager, overlooking various aspects of drug development from preclinical research, Manufacturing to clinical development. Between 2007 and 2013 he was Director of Clinical Operations at Ablynx, where he started as project manager overseeing seamless integration of pharmacology, toxicology, bio analytic, CMC with main priority to set up the clinical

development. In the years before, Kristof held several positions at different pharmaceutical companies (Nycomed and Organon) and CROs (ClinCare Consulting and PRA International).

Finally, Ziphius Vaccines will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11-14, 2021. If you would like to meet the management team, please contact Mathieu Ghadanfar, Business Development Officer and Chief Medical Officer: partnering@ziphius.org.

About Ziphius Vaccines

Ziphius Vaccines NV is a self-amplifying RNA company developing transformative infectious disease vaccines based on messenger RNA (mRNA), in order to create a new generation of medicines. To date, the Company has a portfolio of 10 next generation vaccine candidates targeting a wide range of infectious diseases.

 

Headquartered in Oostkamp, Belgium, Ziphius Vaccines currently has strategic partnerships with experienced executives in the pharmaceutical industry that bring over 100 years of combined expertise in drug development.

Headquarters 

Legeweg 157C,

B-8020 Oostkamp,

Belgium

Email: info@ziphius.org

Development

Heidestraat 19,

9820 Merelbeke,

Belgium

© 2021 Ziphius Vaccines NV

  • LinkedIn Social Icon